Overview

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Status:
Completed
Trial end date:
2016-03-23
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the renal function comparing Certican based immunosuppressive regimens with two different CNIs (Tacrolimus or Cyclosporin A) versus a standard treatment with Mycophenolic Acid and Tacrolimus in de novo renal transplant recipients.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Basiliximab
Cyclosporine
Cyclosporins
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus